tenofovir

Subscribe to Selected New Research on tenofovir

262 relevant articles (29 outcomes, 32 trials/studies) found for this Bio-Agent

Also Known As:

(R)-9-(2-phosphonylmethoxypropyl)adenine; 9-(2-phosphonomethoxypropyl)adenine; 9-(2-phosphonylmethoxypropyl)adenine; 9-(2-phosphonylmethoxypropyl)adenine, (+-)-isomer; 9-(2-phosphonylmethoxypropyl)adenine, (R)-isomer; 9-(2-phosphonylmethoxypropyl)adenine, (S)-isomer; 9-PMPA

Relationship Network

Bio-Agent Context: Research Results

Inorganic Chemicals: 5

Phosphorus Compounds: 87

Phosphorus Acids

Phosphonic Acids: 76

tenofovir: 262

Organic Chemicals: 40

Organophosphorus Compounds: 126

Phosphonic Acids: 76

tenofovir: 262

Heterocyclic Compounds: 23

2-Ring Heterocyclic Compounds

Purines: 341

Adenine: 1360

tenofovir: 262

Experts

1.	Berg, Thomas: 4 articles (10/2006 - 08/2002)
2.	Soriano, Vincent: 3 articles (10/2006 - 09/2005)
3.	Schürmann, Dirk: 3 articles (10/2006 - 08/2002)
4.	van Bömmel, Florian: 3 articles (08/2006 - 08/2002)
5.	Hirschel, Bernard: 2 articles (04/2008 - 01/2008)
6.	Janssen, H L A: 2 articles (03/2008 - 02/2008)
7.	Bruno, Raffaele: 2 articles (05/2007 - 10/2006)
8.	Dore, Gregory J: 2 articles (03/2007 - 01/2007)
9.	Matthews, Gail V: 2 articles (03/2007 - 01/2007)
10.	Carlebach, Amina: 2 articles (10/2006 - 12/2005)

Related Diseases

1.	Infection 12/01/2005 - "CONCLUSIONS: Tenofovir is effective in treating HBV infection in HIV patients" 04/28/2003 - "Tenofovir effective in all stages of the infection]" 12/01/2005 - "Taken together our results strongly encourage further studies to investigate the real impact of tenofovir towards HTLV-1 infection." 11/15/2002 - "In a subsequent study, 2 oral inoculations of 4 juvenile macaques with a mixture of tenofovir DF and SIVmac251 induced persistent infection" 10/01/2008 - "Attenuated infection with failure of tenofovir as prophylaxis has been reported in animal models" Get all the results and reference details, order at left...
2.	Hepatitis B 04/01/2006 - "Tenofovir has significant activity against hepatitis B virus (HBV), but clinical data about its utility for treatment of hepatitis B in patients coinfected with HBV and HIV are limited" 03/01/2004 - "We report an HIV-positive man who re-acquires hepatitis B with evidence of serological protection which then resolves while on anti-retrovirals including tenofovir." 09/01/2003 - "Tenofovir (TDF), a recently approved drug for the treatment of HIV, is also active against hepatitis B" 01/01/2003 - "Tenofovir helps beat hepatitis B." 05/01/2007 - "Safety and tolerability of sequential pegylated IFN-alpha2a and tenofovir for hepatitis B infection in HIV(+) individuals." Get all the results and reference details, order at left...
3.	Viremia 08/01/2004 - "While untreated animals with similarly high viremia developed fatal immunodeficiency within 3-6 months, these tenofovir-treated animals had significantly improved survival (up to 3.5 years)" 10/01/2008 - "CONCLUSIONS: Despite the failure of tenofovir DF/FTC as prophylaxis, selection for drug-resistant transmission did not occur and the blunting of postinfection levels of viremia likely reduced the probability of subsequent forward transmissions during the acute phase" 03/30/2007 - "Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT." 01/01/2007 - "One animal eventually suppressed K65R viremia to undetectable levels for more than 4 years; sequential experiments using CD8+ cell depletion and tenofovir interruption demonstrated that both CD8+ cells and continued tenofovir therapy were required for sustained suppression of viremia" 07/01/2006 - "To determine whether structured treatment interruptions (STI) can induce similar immunologic control of viremia, eight newborn macaques were infected with highly virulent SIVmac251 and started on a tenofovir STI regimen 5 days later" Get all the results and reference details, order at left...
4.	Retroviridae Infections (Infection, Retrovirus) 10/01/2003 - "Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections." 10/01/2003 - "The acyclic nucleoside phosphonates HPMPC (cidofovir), PMEA (adefovir), and PMPA (tenofovir) have proved to be effective in vitro (cell culture systems) and in vivo (animal models and clinical studies) against a wide variety of DNA virus and retrovirus infections: cidofovir against herpesvirus (herpes simplex virus types 1 and 2 varicella-zoster virus, cytomegalovirus [CMV], Epstein-Barr virus, and human herpesviruses 6, 7, and 8), polyomavirus, papillomavirus, adenovirus, and poxvirus (variola virus, cowpox virus, vaccinia virus, molluscum contagiosum virus, and orf virus) infections; adefovir against herpesvirus, hepadnavirus (human hepatitis B virus), and retrovirus (human immunodeficiency virus types 1 [HIV-1] and 2 [HIV-2], simian immunodeficiency virus, and feline immunodeficiency virus) infections; and tenofovir against both hepadnavirus and retrovirus infections" 06/01/2003 - "The acyclic nucleoside phosphonates [HPMPC: cidofovir, Vistide; PMEA: adefovir dipivoxil, Hepsera; and PMPA: tenofovir, Viread] have proven to be effective in vitro (cell culture systems) and in vivo (animal models and clinical studies) against a wide variety of DNA virus and retrovirus infections, for example, cidofovir against herpesvirus [herpes simplex virus type 1 and 2, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus type 6, 7 and 8), polyoma-, papilloma-, adeno- and poxvirus (variola virus, cowpox virus, vaccinia virus, molluscum contagiosum virus and orf) infections; adefovir against herpesvirus, hepadnavirus [human hepatitis B virus] and retrovirus [HIV type-1 and 2, simian immunodeficiency virus and feline immunodeficiency virus] infections; and tenofovir against both hepadna- and retrovirus infections" Get all the results and reference details, order at left...
5.	Acquired Immunodeficiency Syndrome (AIDS) 05/23/2006 - "AIDS drug trial turned away; protests by prostitutes in Cambodia ended Tenofovir testing." 11/01/2008 - "Population pharmacokinetics of tenofovir in AIDS patients." 06/01/2008 - "Assessment of 1177 human immunodeficiency virus (HIV) resistance genotypes at an HIV/AIDS clinic showed a decrease in the incidence of the K65R mutation, from 15.2% of isolates during the period 2002-2004 to 2.7% of isolates during the period 2005-2006 (P < .001), despite elevated and stable rates of tenofovir use" 04/01/2003 - "Checking up on ddI and tenofovir in people with HIV/AIDS." 01/01/2008 - "Acute renal failure in an AIDS patient on tenofovir: a case report." Get all the results and reference details, order at left...
101 Diseases and 262 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	pinacolyl methylphosphonic acid
2.	adefovir
3.	RNA-Directed DNA Polymerase (Reverse Transcriptase)
4.	Lamivudine (3TC)
5.	Adenine
6.	cidofovir (Vistide)
7.	Phosphonic Acids (Phosphonates)
8.	Carbon Monoxide
9.	tenofovir disoproxil (Viread)
10.	emtricitabine (Emtriva)
282 Drugs and Important Bio-Agents and 189 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Renal Replacement Therapy (Therapies, Renal Replacement)
2.	Highly Active Antiretroviral Therapy (HAART)
3.	Drug Therapy (Chemotherapy)
4.	Transplants (Transplant)
5.	Transplantation (Transplant Recipients)
9 Therapies and Procedures and 19 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>